 | • レポートコード：MRC2Q12-19252 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、重症筋無力症治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 重症筋無力症治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 重症筋無力症治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 重症筋無力症治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの重症筋無力症治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の重症筋無力症治療の売上および2028年までの予測に焦点を当てています。 重症筋無力症治療のグローバル主要企業には、Amneal Pharmaceuticals, Inc.、Astellas Pharma, Inc.、Avadel Pharmaceuticals PLC、Bausch Health Companies Inc.、CSL Behring、CuraVac, Inc.、Argenx SE、GlaxoSmithKline plc、Immunovant, Inc.、Mitsubishi Tanabe Pharma Corp.、Ra Pharmaceuticals, Inc.、Takeda Pharmaceutical Co., Ltd.、UCB Pharma、Valeant Pharmaceuticals International, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 重症筋無力症治療市場は、タイプとアプリケーションによって区分されます。世界の重症筋無力症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 内科的治療、手術治療 【アプリケーション別セグメント】 病院、専門外来 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 重症筋無力症治療製品概要 - タイプ別市場（内科的治療、手術治療） - アプリケーション別市場（病院、専門外来） - 調査の目的 ・エグゼクティブサマリー - 世界の重症筋無力症治療販売量予測2017-2028 - 世界の重症筋無力症治療売上予測2017-2028 - 重症筋無力症治療の地域別販売量 - 重症筋無力症治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別重症筋無力症治療販売量 - 主要メーカー別重症筋無力症治療売上 - 主要メーカー別重症筋無力症治療価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（内科的治療、手術治療） - 重症筋無力症治療のタイプ別販売量 - 重症筋無力症治療のタイプ別売上 - 重症筋無力症治療のタイプ別価格 ・アプリケーション別市場規模（病院、専門外来） - 重症筋無力症治療のアプリケーション別販売量 - 重症筋無力症治療のアプリケーション別売上 - 重症筋無力症治療のアプリケーション別価格 ・北米市場 - 北米の重症筋無力症治療市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの重症筋無力症治療市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の重症筋無力症治療市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の重症筋無力症治療市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの重症筋無力症治療市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症治療市場規模（トルコ、サウジアラビア） ・企業情報 Amneal Pharmaceuticals, Inc.、Astellas Pharma, Inc.、Avadel Pharmaceuticals PLC、Bausch Health Companies Inc.、CSL Behring、CuraVac, Inc.、Argenx SE、GlaxoSmithKline plc、Immunovant, Inc.、Mitsubishi Tanabe Pharma Corp.、Ra Pharmaceuticals, Inc.、Takeda Pharmaceutical Co., Ltd.、UCB Pharma、Valeant Pharmaceuticals International, Inc. ・産業チェーン及び販売チャネル分析 - 重症筋無力症治療の産業チェーン分析 - 重症筋無力症治療の原材料 - 重症筋無力症治療の生産プロセス - 重症筋無力症治療の販売及びマーケティング - 重症筋無力症治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 重症筋無力症治療の産業動向 - 重症筋無力症治療のマーケットドライバー - 重症筋無力症治療の課題 - 重症筋無力症治療の阻害要因 ・主な調査結果 |
Drug therapy for MG includes: (1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Myasthenia Gravis Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Myasthenia Gravis Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Myasthenia Gravis Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Myasthenia Gravis Treatment include Amneal Pharmaceuticals, Inc., Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., CSL Behring, CuraVac, Inc., Argenx SE, GlaxoSmithKline plc and Immunovant, Inc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Myasthenia Gravis Treatment manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Myasthenia Gravis Treatment market. Further, it explains the major drivers and regional dynamics of the global Myasthenia Gravis Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Amneal Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Avadel Pharmaceuticals PLC
Bausch Health Companies Inc.
CSL Behring
CuraVac, Inc.
Argenx SE
GlaxoSmithKline plc
Immunovant, Inc.
Mitsubishi Tanabe Pharma Corp.
Ra Pharmaceuticals, Inc.
Takeda Pharmaceutical Co., Ltd.
UCB Pharma
Valeant Pharmaceuticals International, Inc.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Myasthenia Gravis Treatment Segment by Type
Medical Treatement
Operation Treatment
Myasthenia Gravis Treatment Segment by Application
Hospital
Specialist Outpatient Clinic
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Myasthenia Gravis Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Myasthenia Gravis Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Myasthenia Gravis Treatment, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Myasthenia Gravis Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Myasthenia Gravis Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Myasthenia Gravis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Myasthenia Gravis Treatment sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amneal Pharmaceuticals, Inc., Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., CSL Behring, CuraVac, Inc., Argenx SE, GlaxoSmithKline plc and Immunovant, Inc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Myasthenia Gravis Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Myasthenia Gravis Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Myasthenia Gravis Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Myasthenia Gravis Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Myasthenia Gravis Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Medical Treatement
1.2.3 Operation Treatment
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Outpatient Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Myasthenia Gravis Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Myasthenia Gravis Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Myasthenia Gravis Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Myasthenia Gravis Treatment Sales by Region
2.4.1 Global Myasthenia Gravis Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Myasthenia Gravis Treatment by Region (2023-2028)
2.5 Global Myasthenia Gravis Treatment Revenue by Region
2.5.1 Global Myasthenia Gravis Treatment Revenue by Region (2017-2022)
2.5.2 Global Myasthenia Gravis Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Myasthenia Gravis Treatment Sales by Manufacturers
3.1.1 Global Top Myasthenia Gravis Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Myasthenia Gravis Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Myasthenia Gravis Treatment in 2021
3.2 Global Myasthenia Gravis Treatment Revenue by Manufacturers
3.2.1 Global Myasthenia Gravis Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Myasthenia Gravis Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Myasthenia Gravis Treatment Revenue in 2021
3.3 Global Myasthenia Gravis Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Myasthenia Gravis Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Myasthenia Gravis Treatment Sales by Type
4.1.1 Global Myasthenia Gravis Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Myasthenia Gravis Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Type (2017-2028)
4.2 Global Myasthenia Gravis Treatment Revenue by Type
4.2.1 Global Myasthenia Gravis Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Myasthenia Gravis Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Myasthenia Gravis Treatment Price by Type
4.3.1 Global Myasthenia Gravis Treatment Price by Type (2017-2022)
4.3.2 Global Myasthenia Gravis Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Myasthenia Gravis Treatment Sales by Application
5.1.1 Global Myasthenia Gravis Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Myasthenia Gravis Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Application (2017-2028)
5.2 Global Myasthenia Gravis Treatment Revenue by Application
5.2.1 Global Myasthenia Gravis Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Myasthenia Gravis Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Myasthenia Gravis Treatment Price by Application
5.3.1 Global Myasthenia Gravis Treatment Price by Application (2017-2022)
5.3.2 Global Myasthenia Gravis Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Myasthenia Gravis Treatment Market Size by Type
6.1.1 North America Myasthenia Gravis Treatment Sales by Type (2017-2028)
6.1.2 North America Myasthenia Gravis Treatment Revenue by Type (2017-2028)
6.2 North America Myasthenia Gravis Treatment Market Size by Application
6.2.1 North America Myasthenia Gravis Treatment Sales by Application (2017-2028)
6.2.2 North America Myasthenia Gravis Treatment Revenue by Application (2017-2028)
6.3 North America Myasthenia Gravis Treatment Market Size by Country
6.3.1 North America Myasthenia Gravis Treatment Sales by Country (2017-2028)
6.3.2 North America Myasthenia Gravis Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Myasthenia Gravis Treatment Market Size by Type
7.1.1 Europe Myasthenia Gravis Treatment Sales by Type (2017-2028)
7.1.2 Europe Myasthenia Gravis Treatment Revenue by Type (2017-2028)
7.2 Europe Myasthenia Gravis Treatment Market Size by Application
7.2.1 Europe Myasthenia Gravis Treatment Sales by Application (2017-2028)
7.2.2 Europe Myasthenia Gravis Treatment Revenue by Application (2017-2028)
7.3 Europe Myasthenia Gravis Treatment Market Size by Country
7.3.1 Europe Myasthenia Gravis Treatment Sales by Country (2017-2028)
7.3.2 Europe Myasthenia Gravis Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Myasthenia Gravis Treatment Market Size by Type
8.1.1 Asia Pacific Myasthenia Gravis Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Myasthenia Gravis Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Myasthenia Gravis Treatment Market Size by Application
8.2.1 Asia Pacific Myasthenia Gravis Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Myasthenia Gravis Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Myasthenia Gravis Treatment Market Size by Region
8.3.1 Asia Pacific Myasthenia Gravis Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Myasthenia Gravis Treatment Market Size by Type
9.1.1 Latin America Myasthenia Gravis Treatment Sales by Type (2017-2028)
9.1.2 Latin America Myasthenia Gravis Treatment Revenue by Type (2017-2028)
9.2 Latin America Myasthenia Gravis Treatment Market Size by Application
9.2.1 Latin America Myasthenia Gravis Treatment Sales by Application (2017-2028)
9.2.2 Latin America Myasthenia Gravis Treatment Revenue by Application (2017-2028)
9.3 Latin America Myasthenia Gravis Treatment Market Size by Country
9.3.1 Latin America Myasthenia Gravis Treatment Sales by Country (2017-2028)
9.3.2 Latin America Myasthenia Gravis Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Myasthenia Gravis Treatment Market Size by Type
10.1.1 Middle East and Africa Myasthenia Gravis Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Myasthenia Gravis Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Myasthenia Gravis Treatment Market Size by Application
10.2.1 Middle East and Africa Myasthenia Gravis Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Myasthenia Gravis Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Myasthenia Gravis Treatment Market Size by Country
10.3.1 Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Myasthenia Gravis Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Amneal Pharmaceuticals, Inc.
11.1.1 Amneal Pharmaceuticals, Inc. Corporation Information
11.1.2 Amneal Pharmaceuticals, Inc. Overview
11.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amneal Pharmaceuticals, Inc. Recent Developments
11.2 Astellas Pharma, Inc.
11.2.1 Astellas Pharma, Inc. Corporation Information
11.2.2 Astellas Pharma, Inc. Overview
11.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Astellas Pharma, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Astellas Pharma, Inc. Recent Developments
11.3 Avadel Pharmaceuticals PLC
11.3.1 Avadel Pharmaceuticals PLC Corporation Information
11.3.2 Avadel Pharmaceuticals PLC Overview
11.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Avadel Pharmaceuticals PLC Recent Developments
11.4 Bausch Health Companies Inc.
11.4.1 Bausch Health Companies Inc. Corporation Information
11.4.2 Bausch Health Companies Inc. Overview
11.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bausch Health Companies Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bausch Health Companies Inc. Recent Developments
11.5 CSL Behring
11.5.1 CSL Behring Corporation Information
11.5.2 CSL Behring Overview
11.5.3 CSL Behring Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 CSL Behring Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 CSL Behring Recent Developments
11.6 CuraVac, Inc.
11.6.1 CuraVac, Inc. Corporation Information
11.6.2 CuraVac, Inc. Overview
11.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 CuraVac, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 CuraVac, Inc. Recent Developments
11.7 Argenx SE
11.7.1 Argenx SE Corporation Information
11.7.2 Argenx SE Overview
11.7.3 Argenx SE Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Argenx SE Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Argenx SE Recent Developments
11.8 GlaxoSmithKline plc
11.8.1 GlaxoSmithKline plc Corporation Information
11.8.2 GlaxoSmithKline plc Overview
11.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 GlaxoSmithKline plc Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 GlaxoSmithKline plc Recent Developments
11.9 Immunovant, Inc.
11.9.1 Immunovant, Inc. Corporation Information
11.9.2 Immunovant, Inc. Overview
11.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Immunovant, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Immunovant, Inc. Recent Developments
11.10 Mitsubishi Tanabe Pharma Corp.
11.10.1 Mitsubishi Tanabe Pharma Corp. Corporation Information
11.10.2 Mitsubishi Tanabe Pharma Corp. Overview
11.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Mitsubishi Tanabe Pharma Corp. Recent Developments
11.11 Ra Pharmaceuticals, Inc.
11.11.1 Ra Pharmaceuticals, Inc. Corporation Information
11.11.2 Ra Pharmaceuticals, Inc. Overview
11.11.3 Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Ra Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Ra Pharmaceuticals, Inc. Recent Developments
11.12 Takeda Pharmaceutical Co., Ltd.
11.12.1 Takeda Pharmaceutical Co., Ltd. Corporation Information
11.12.2 Takeda Pharmaceutical Co., Ltd. Overview
11.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Takeda Pharmaceutical Co., Ltd. Recent Developments
11.13 UCB Pharma
11.13.1 UCB Pharma Corporation Information
11.13.2 UCB Pharma Overview
11.13.3 UCB Pharma Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 UCB Pharma Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 UCB Pharma Recent Developments
11.14 Valeant Pharmaceuticals International, Inc.
11.14.1 Valeant Pharmaceuticals International, Inc. Corporation Information
11.14.2 Valeant Pharmaceuticals International, Inc. Overview
11.14.3 Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Valeant Pharmaceuticals International, Inc. Myasthenia Gravis Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Valeant Pharmaceuticals International, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Myasthenia Gravis Treatment Industry Chain Analysis
12.2 Myasthenia Gravis Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myasthenia Gravis Treatment Production Mode & Process
12.4 Myasthenia Gravis Treatment Sales and Marketing
12.4.1 Myasthenia Gravis Treatment Sales Channels
12.4.2 Myasthenia Gravis Treatment Distributors
12.5 Myasthenia Gravis Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Myasthenia Gravis Treatment Industry Trends
13.2 Myasthenia Gravis Treatment Market Drivers
13.3 Myasthenia Gravis Treatment Market Challenges
13.4 Myasthenia Gravis Treatment Market Restraints
14 Key Findings in The Global Myasthenia Gravis Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer